Expanding the limits of cancer therapies
Hemerion develops novel cancer therapies that blend photonics, medecine and biotechnology. Its first breakthrough technology addresses glioblastoma as a complement to neurosurgery. Its efficacy is currently being evaluated in clinical trials.
Nature highlights the first clinical trials of Hemerion's technologiesRead more
Dr Maximilien Vermandel, Hemerion's founder, presents the news perspectives opened up by Hemerion to treat glioblastomas."